Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 14/20 | 0.68 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | PI4KA | P42356 | 2/20 | 0.53 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.53 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357203 | 0.85 | MAP4K4 (0.79) | MAP4K4 | |
| SCHEMBL6442231 | 0.84 | NR4A2 (0.56) | MAP4K4NR4A2PI4KAPI4K2BPI4K2A | |
| SCHEMBL15587530 | 0.81 | MAP4K4 (1.00) | MAP4K4 | |
| SCHEMBL15587271 | 0.80 | MAP4K4 (1.00) | MAP4K4 | |
| SCHEMBL15587286 | 0.80 | MAP4K4 (1.00) | MAP4K4 | |
| SCHEMBL29713890 | 0.79 | MAP4K4 (0.66) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4692556 | 0.79 | MAP4K4 (0.66) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29793572 | 0.79 | PDE4A (0.57) | MAP4K4NR4A2CYP1A2CYP2D6 | |
| SCHEMBL856909 | 0.79 | PDE4A (0.57) | MAP4K4NR4A2CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL10969363 | 0.78 | MAP4K4 (0.64) | MAP4K4PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-11311520-B2 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-04-26 | — | — | US | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210085656-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-25 | — | — | US | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20190350910-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-11-21 | — | — | US | disclosed |
| EP-3200789-B1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018134148-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-26 | — | — | WO | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
| US-4543356-A | Quinazoline derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-09-24 | — | — | US | disclosed |
| EP-0030156-B1 | QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-21 | — | — | EP | disclosed |
| US-4429126-A | ANTIASTHMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-01-31 | — | — | US | disclosed |
| US-4377580-A | ANTIALLERGENIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-03-22 | — | — | US | disclosed |
| EP-0030156-A1 | Quinazoline derivatives, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-10 | — | — | EP | disclosed |
| US-3985749-A | Process for preparation of 4-aminoquinazoline | EASTMAN KODAK COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350910-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, MAP4K5 | MAP4K4 9/4885NR4A2 1514/4885PI4KA 152/4885 |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | MAP4K4 1801/4885NR4A2 6/4885PI4KA 2832/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | MAP4K4 1801/4885NR4A2 6/4885PI4KA 2832/4885 |
| US-20210085656-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, MAP4K5 | MAP4K4 9/4885NR4A2 1613/4885PI4KA 151/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | MAP4K4 1837/4885NR4A2 6/4885PI4KA 3079/4885 |
| US-11311520-B2 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | MKNK1, MKNK2, MAP4K5 | MAP4K4 9/4885NR4A2 1613/4885PI4KA 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.